Protocol Ledger

NCT05947955 · Phase II · RECRUITING

Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)

Interventional Phase II clinical trial protocol NCT05947955 sponsored by BioAegis Therapeutics in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-03 Enrollment: 600 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05947955
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)600 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05947955
Protocol FieldVerified Registry Value
NCT IdentifierNCT05947955
Consolidated Lead SponsorBioAegis Therapeutics
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment600 participants (ESTIMATED)
Registered Start Date2024-10-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI